Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:

Size: px
Start display at page:

Download "Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:"

Transcription

1 Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the following organizations and companies: Research Funding: National Institute of Health University of California Advising: Coalition for Pulmonary Fibrosis Scientific Consulting: Actelion Amira Pharmaceuticals Gilead Science Overview This talk is about pharmacological therapy in interstitial lung disease (ILD) Traditional Paradigm Injury inflammation fibrosis I want you to understand: When to treat What to use How to use it Repetitive injury leads to the development of widespread inflammation and/or fibrosis 1

2 Applies to most ILDs Applies to most ILDs Interstitial Lung Disease Interstitial Lung Disease Exposure-related: - Occupational - Environmental - Avocational - Medication Idiopathic interstitial pneumonia (IIP) Desquamative interstitial pneumonia (DIP) Acute interstitial pneumonia (AIP) Idiopathic pulmonary fibrosis (IPF) Connective tissue disease: - Scleroderma - Rheum. arth - Sjogrens Respiratory bronchiolitis interstitial lung dis. (RBILD) Cryptogenic organizing pneumonia (COP) Sarcoidosis Other: - Vasculitis/Diffuse alveolar hemorrhage (DAH) - Langherhans cell histiocytosis (LCH) - Eosinophilic pneumonias - Neurofibromatosis - Inherited disorders - Chronic aspiration - Inflammatory bowel disease Exposure-related: - Occupational - Environmental - Avocational - Medication Idiopathic interstitial pneumonia (IIP) Desquamative interstitial pneumonia (DIP) Acute interstitial pneumonia (AIP) Idiopathic pulmonary fibrosis (IPF) Connective tissue disease: - Scleroderma - Rheum. arth - Sjogrens Respiratory bronchiolitis interstitial lung dis. (RBILD) Cryptogenic organizing pneumonia (COP) Sarcoidosis Other: - Vasculitis/Diffuse alveolar hemorrhage (DAH) - Langherhans cell histiocytosis (LCH) - Eosinophilic pneumonias - Neurofibromatosis - Inherited disorders - Chronic aspiration - Inflammatory bowel disease Nonspecific interstitial pneumonia (NSIP) Lymphocytic interstitial pneumonia (LIP) Nonspecific interstitial pneumonia (NSIP) Lymphocytic interstitial pneumonia (LIP) ILD Treatment: Non-IPF ILD that is likely to resolve (sarcoid, COP, cellular HP, DIP, LCH) Prednisone ILD that is unlikely to resolve (CTILD, fibrotic NSIP, fibrotic HP) Prednisone and/or immunomodulatory therapy (azathioprine, cyclophosphamide, mycophenolate) Image courtesy of Kirk Jones, MD 2

3 When to treat When to treat Side effects Adverse reactions Cost BENEFIT RISK When to treat Dosing of therapy Prednisone: 0.5 mg/kg/day (less in sarcoidosis) Azathioprine: 2 mg/kg/day Cyclophosphamide: 2 mg/kg/day (oral) Mycophenolate: 2 grams/day 3

4 Timing of dual agent therapy What about IPF? Labs: Q 2wk Q mo Interstitial Lung Disease Prednisone dose (mg/kg ) None Full Half None Second agent ( ) Exposure-related: - Occupational - Environmental - Avocational - Medication Idiopathic interstitial pneumonia (IIP) Desquamative interstitial pneumonia (DIP) Acute interstitial pneumonia (AIP) Idiopathic pulmonary fibrosis (IPF) Connective tissue disease: - Scleroderma - Rheum. arth - Sjogrens Respiratory bronchiolitis interstitial lung dis. (RBILD) Cryptogenic organizing pneumonia (COP) Sarcoidosis Other: - Vasculitis/Diffuse alveolar hemorrhage (DAH) - Langherhans cell histiocytosis (LCH) - Eosinophilic pneumonias - Neurofibromatosis - Inherited disorders - Chronic aspiration - Inflammatory bowel disease Start 1mo 2mo 3mo 4mo 5mo 6mo Nonspecific interstitial pneumonia (NSIP) Lymphocytic interstitial pneumonia (LIP) Treatment is inconsistent Traditional Therapy Percent of respondents Corticosteroid Prednisone (0.5 mg/kg/d, tapered over 2-3 months) + Immunomodulator Azathioprine (2 mg/kg/d) Cyclophosphamide (2 mg/kg/d) Mycophenolate (2 grams/d) Collard Resp Med 2007;101:2011 4

5 Traditional therapy Treatment Relative risk No therapy % CI p value Prednisone to Prednisone plus immunomodulator to Douglas AJRCCM 2000;161:1172 Traditional therapy Some patients still respond P = 0.58 Patients treated with prednisone Response defined as 10 point change in CRP score Response (26%) (82) (82) Stable (37%) No response (37%)? Collard et al. Chest 2004;125:2169 Gay AJRCCM 1998;157:1063 5

6 Data are Lacking For patients with a definite diagnosis of IPF there is no evidence that coticosteroid therapy plays a role in modifying the course of disease. Interferon gamma 1b Acetylcysteine Pirfenidone Novel therapies? No controlled clinical trials in this area Richeldi Cochrane Review 2006 Biological rationale Interferon gamma 1b INFγ limits fibroblast proliferation (Pfeffer et al. Exp Cell Res 1979;121:111) INFγ limits TGFβ-induced collagen production (Eikelberg et al. FASEB J 2001;15:797) IPF lung appears to have decreased INFγ (Majumdar et al. Eur Resp J 1999;14:251) 6

7 Progression-free survival 330 patients INFγ vs. Placebo 1 endpoint: progression free survival (death, drop in FVC, DLCO, or A-a gradient) Raghu NEJM 2004;350:125 Raghu NEJM 2004;350:125 Overall survival INSPIRE 826 pts preserved FVC INFγ vs. placebo 1 endpoint: survival 115 events DISCONTINUED by data safety board for lack of benefit (i.e. reduction in risk of death of 33% or greater) Raghu NEJM 2004;350:125 King Lancet 2009;374:222 7

8 Biological rationale Acetylcysteine Control NAC Treatment with NAC ameliorates bleomycin-induced pulmonary fibrosis in rats. Cortijo et al. Eur Respir L 2001;17:1228 Biological rationale Patients with IPF have decreased levels of glutathione in sputum and BAL fluid 155 subjects Acetylcysteine +/- prednisone/azathioprine 1 endpoint: change in vital capacity at 12 months Beeh et al. Eur Respir J 2002;19:1119 Demedts NEJM 2005;353:2229 8

9 Results Results P = 0.02 P = 0.02 Azuma 2005 Raghu 2004 SHIONOGI Raghu 2008 King 2008 CAPACITY 1 CAPACITY 2 Demedts NEJM 2005;353:2229 Demedts NEJM 2005;353:2229 Biological rationale Pirfenidone Iyer et al. J Pharmacol Exp Ther 1999;291:367 9

10 Shionogi Study Phase 3 double blind randomized controlled 275 subjects with IPF randomized 2:1:2 (high dose, low dose, placebo) Age Desaturation 5% with walk test Lowest SpO2 85% on room air Primary outcome: Change in vital capacity at 52 weeks Variable Shionogi Study Pirfenidone, high dose (n = 108) Pirfenidone, low dose (n = 55) Placebo (n = 104) Age Male gender 79% 86% 78% Smoking history 80% 78% 80% Steroid use 8% 11% 6% Lung biopsy 24% 29% 27% VC % predicted DLCO % predicted Desaturation on walk test 32% 35% 23% Taniguchi ERJ 2010;35:821 Taniguchi ERJ 2010;35:821 Shionogi Study Shionogi Study Taniguchi ERJ 2010;35:821 Taniguchi ERJ 2010;35:821 10

11 Limitations Primary endpoint changed Initially lowest oxygen saturation during walk test Done after data reviewed Limitations Primary endpoint changed Initially lowest oxygen saturation during walk test Done after data reviewed Substantial missing data 30-40% across groups Statistical methodology problematic Collard ERJ 2010;35:728 Collard ERJ 2010;35:728 Limitations Limitations = crude mean change Primary endpoint changed Initially lowest oxygen saturation during walk test Done after data reviewed Substantial missing data 30-40% across groups Statistical methodology problematic No patient centered outcome data Increased photosensitivity (>50%), elevated GGT Morbidity could negate marginal physiological benefit Taniguchi ERJ 2010;35:821 Collard ERJ 2010;35:728 11

12 Capacity Studies Phase 3 double blind randomized controlled PIPF006: 344 subjects randomized 1:1 (high dose, placebo) PIPF004: 435 subjects randomized 2:1:2 (high dose, low dose, placebo) Primary outcome: Change in forced vital capacity at 72 weeks Capacity Studies Inclusion criteria Age Diagnosis of IPF within 48 months FVC > 50%, DLCO > 35% Exclusion criteria Significant COPD FDA Briefing Booklet ( CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM pdf) FDA Briefing Booklet ( CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM pdf) Capacity Studies Capacity Studies Change in FVC % P = = Change in FVC % Azuma, Raghu, Raghu, 2008 King, 2008 P = = = 004 = 004 P < P < FDA Briefing Booklet ( CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM pdf) FDA Briefing Booklet ( CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM pdf) 12

13 Capacity Studies Capacity Studies Relative reduction in FVC decline (%) = 006 = 004 PIPF006 PIPF004 Secondary Endpoints Time to worsening IPF Progression-free survival MWT distance change Dyspnea (UCSD SOBQ) change Survival time CAPACITY ATS Presentation, May 20 th, 2009 CAPACITY ATS Presentation, May 20 th, 2009 Pirfenidone Conclusions Do the data provide substantial evidence that pirfenidone provides a clinically meaningful beneficial effect? Pirfenidone Conclusions Do the data provide substantial evidence that pirfenidone provides a clinically meaningful beneficial effect? Has the safety of pirfenidone been adequately assessed? 13

14 Pirfenidone Conclusions Would you recommend approval of pirfenidone for the treatment of patients with IPF? Treatment of ILD: Algorithm Patient with ILD General Management (What criteria should be used for deciding this?) Manage comorbidities Pulmonary rehabilitation Oxygen therapy Lung Transplantation IPF? NO Prednisone +/- immunomodulator YES Enroll in a clinical trial if eligible No therapy NAC (+/-Pred/Aza) Pirfenidone Thank you! UCSF ILD Program 400 Parnassus Avenue, 5 th Floor Chest Practice (phone) 14

Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline

Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification

More information

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary

More information

DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?

DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? NIHR Southampton Respiratory Biomedical Research Unit DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? Fibrosing Interstitial Lung Diseases CPFS/WASOG/AIPO/ERS

More information

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.

More information

A Review of Interstitial Lung Diseases

A Review of Interstitial Lung Diseases Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification

More information

A Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco

A Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification

More information

New Horizons The Future of IPF and ILD

New Horizons The Future of IPF and ILD New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco

More information

Wim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art.

Wim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art. nterstitial ungdiseases euven Department of pneumology Unit for interstitial lung diseases University Hospitals Leuven March 12 th 2015 Interstitial lung diseases state of the art Treatment of idiopathic

More information

INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)

INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) THE INCREASE STUDY INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) Peter Smith, PharmD Senior Director Product Development, United Therapeutics Corporation 2 SAFE

More information

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to

More information

Timely Topics in Pulmonary Medicine

Timely Topics in Pulmonary Medicine Disclosures Timely Topics in Pulmonary Medicine I have nothing to disclose! Lorriana Leard, MD Associate Professor of Clinical Medicine Chief of Clinical Operations UCSF Pulmonary, Critical Care, Allergy

More information

Controversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)

Controversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints

More information

Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy

Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe

More information

New Therapies and Trials in IPF

New Therapies and Trials in IPF Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: New Therapies and Trials in IPF Talmadge E. King, Jr., M.D. Julius R. Krevans

More information

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation

More information

Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic

Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO

More information

Progress in Idiopathic Pulmonary Fibrosis

Progress in Idiopathic Pulmonary Fibrosis Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim

More information

DIAGNOSTIC NOTE TEMPLATE

DIAGNOSTIC NOTE TEMPLATE DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the

More information

Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas

Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University

More information

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +

More information

Conflicts of Interest. Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck

Conflicts of Interest. Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck Conflicts of Interest Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck The Idiopathic Interstitial Pneumonias Idiopathic pulmonary

More information

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment

More information

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial

More information

Management of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures

Management of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board

More information

Diagnosing ILD. What is important in 2016? Chris Grainge

Diagnosing ILD. What is important in 2016? Chris Grainge Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a

More information

INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)

INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program

More information

Outline Definition of Terms: Lexicon. Traction Bronchiectasis

Outline Definition of Terms: Lexicon. Traction Bronchiectasis HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of

More information

International consensus statement on idiopathic pulmonary fibrosis

International consensus statement on idiopathic pulmonary fibrosis Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic

More information

Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis

Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives

More information

Diffuse Interstitial Lung Diseases: Is There Really Anything New?

Diffuse Interstitial Lung Diseases: Is There Really Anything New? : Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There

More information

Non-neoplastic Lung Disease II

Non-neoplastic Lung Disease II Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,

More information

Interstitial Lung Disease (ILD)

Interstitial Lung Disease (ILD) Interstitial Lung Disease (ILD) ILD comprises more than 130 distinct disorders Characterized by cellular proliferation, cellular infiltration, and/or fibrosis of the lung parenchyma not due to infection

More information

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Annual Rheumatology & Therapeutics Review for Organizations & Societies Annual Rheumatology & Therapeutics Review for Organizations & Societies A Rheumatologist s Approach to Interstitial Lung Disease Outline ILD classification and patterns in CTD The clinical landscape and

More information

Current Management of IPF and. Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine

Current Management of IPF and. Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine Current Management of IPF and fibrosing ILDs Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine Introduction Idiopathic pulmonary fibrosis clinical course is variable and long term survival is poor Therapy

More information

OFEV MEDIA BACKGROUNDER

OFEV MEDIA BACKGROUNDER OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small

More information

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,

More information

Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis

Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline Online Supplement Ganesh Raghu, Bram Rochwerg, Yuan

More information

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling

More information

Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis

Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis original article Randomized Trial of in Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* ABSTRACT Background has been suggested as a beneficial treatment for idiopathic

More information

Disclosures. Integrated Approach to Treating CTD-ILD. Limitations. Relevant items to consider. Other than for SSc-ILD, no controlled data

Disclosures. Integrated Approach to Treating CTD-ILD. Limitations. Relevant items to consider. Other than for SSc-ILD, no controlled data Integrated Approach to Treating CTD-ILD Industry relationships: Disclosures Aryeh Fischer, MD Associate Professor of Medicine Division of Rheumatology Division of Pulmonary Sciences and Critical Care Medicine

More information

Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis

Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis Thorax Online First, published on March 22, 2012 as 10.1136/thoraxjnl-2011-201184 Interstitial lung disease < Additional materials are published online only. To view these files please visit the journal

More information

NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP

NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic

More information

IDIOPATHIC PULMONARY FIBROSIS UPDATE

IDIOPATHIC PULMONARY FIBROSIS UPDATE IDIOPATHIC PULMONARY FIBROSIS UPDATE The Importance of Early Recognition and Referral 1 Learning objectives Recognize the importance of early diagnosis and treatment of idiopathic pulmonary fibrosis (IPF)

More information

Presente e futuro della terapia della fibrosi polmonare idiopatica

Presente e futuro della terapia della fibrosi polmonare idiopatica Presente e futuro della terapia della fibrosi polmonare idiopatica Antonella Caminati U.O. di Pneumologia e Terapia Semi Intensiva Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Osp.

More information

Disclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None

Disclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona

More information

Idiopathic pulmonary fibrosis (IPF) is a progressive. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes

Idiopathic pulmonary fibrosis (IPF) is a progressive. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Eur Respir Rev 2012; 21: 124, 161 167 DOI: 10.1183/09059180.00001112 CopyrightßERS 2012 REVIEW: IPF Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Vincent

More information

Differential diagnosis

Differential diagnosis Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential

More information

Manish Powari Regional Training Day 10/12/2014

Manish Powari Regional Training Day 10/12/2014 Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases

More information

Lines and crackles. Making sense of ILD

Lines and crackles. Making sense of ILD Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to

More information

Definition, classification and epidemiology

Definition, classification and epidemiology Interstitial Lung Diseases Definition, classification and epidemiology Haluk Türktaş Professor of Pulmonary Medicine Gazi University Ankara Interstitial Lung Diseases Definition of ILD A diverse group

More information

Careful histopathological evaluation has shown the traditionally clinical diagnosis of

Careful histopathological evaluation has shown the traditionally clinical diagnosis of Demystifying Idiopathic Interstitial Pneumonia Harold R. Collard, MD; Talmadge E. King, Jr, MD REVIEW ARTICLE Careful histopathological evaluation has shown the traditionally clinical diagnosis of idiopathic

More information

NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis

NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis Mark J Rumbak, MD Division Director Pulmonary, Critical Care and Sleep Medicine Morsani College of Medicine University of South Florida, Tampa

More information

Guidelines for Diagnosis and Treatment of IPF

Guidelines for Diagnosis and Treatment of IPF Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease

More information

CTD-related Lung Disease

CTD-related Lung Disease 13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of

More information

Pathologic Assessment of Interstitial Lung Disease

Pathologic Assessment of Interstitial Lung Disease Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology

More information

NINTEDANIB MEDIA BACKGROUNDER

NINTEDANIB MEDIA BACKGROUNDER NINTEDANIB MEDIA BACKGROUNDER 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. International treatment guidelines for IPF 1. What is nintedanib? Nintedanib (OFEV a ) is a small molecule

More information

Limitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis

Limitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Limitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis JMAJ 46(11): 475 482, 2003 Kingo CHIDA Associate Professor, Second Division,

More information

New approaches to the design of clinical trials in idiopathic pulmonary fibrosis

New approaches to the design of clinical trials in idiopathic pulmonary fibrosis New approaches to the design of clinical trials in idiopathic pulmonary fibrosis Clin. Invest. (2013) 3(6), 531 544 Idiopathic pulmonary fibrosis (IPF) is one of the major challenges for respiratory medicine,

More information

Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis

Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis ORIGINAL ARTICLE INTERSTITIAL LUNG DISEASES Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis Brett Ley 1, Williamson Z. Bradford 2, Derek Weycker 3, Eric Vittinghoff

More information

Colorado Pharmacists Society Annual Meeting June 21 st & 22 nd, 2018

Colorado Pharmacists Society Annual Meeting June 21 st & 22 nd, 2018 Interstitial Lung Disease: Focus for the pharmacist Susan Tallieu, MSN, APN, ACNP-BC University of Colorado Anschutz Campus Division of Pulmonary Medicine and Critical Care Colorado Pharmacists Society

More information

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study 36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E

More information

Evidence-based treatment strategies in idiopathic pulmonary fibrosis

Evidence-based treatment strategies in idiopathic pulmonary fibrosis Eur Respir Rev 2013; 22: 128, 163 168 DOI: 10.1183/09059180.00001013 CopyrightßERS 2013 REVIEW Evidence-based treatment strategies in idiopathic pulmonary fibrosis Jürgen Behr ABSTRACT: Recently updated

More information

Unpaid scientific collaborator & advisor with Veracyte, Inc.

Unpaid scientific collaborator & advisor with Veracyte, Inc. Diagnosis and Classification of Idiopathic Interstitial Pneumonias: Role of Histopathology in the Golden Age of Consensus Jeffrey L. Myers, M.D. A. James French Professor of Diagnostic Pathology Vice Chair

More information

Emerging Therapies for Lung Fibrosis. Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow

Emerging Therapies for Lung Fibrosis. Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow Emerging Therapies for Lung Fibrosis Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow Lung Fibrosis/Interstitial Lung Disease Disease that affects the tissue that supports the lungs alveoli

More information

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives

More information

Until approximately 40 yrs ago, clinical. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis REVIEW: IPF

Until approximately 40 yrs ago, clinical. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis REVIEW: IPF Eur Respir Rev 2012; 21: 124, 147 151 DOI: 10.1183/09059180.00000912 CopyrightßERS 2012 REVIEW: IPF Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis Luca Richeldi ABSTRACT:

More information

New Drug Evaluation: Pirfenidone capsules, oral

New Drug Evaluation: Pirfenidone capsules, oral Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Disclosures. IPF Medications: Practical Experience. Prednisone, Azathioprine, N acyetylcysteine. Case 1. Brett Ley, MD, MAS Assistant Professor, UCSF

Disclosures. IPF Medications: Practical Experience. Prednisone, Azathioprine, N acyetylcysteine. Case 1. Brett Ley, MD, MAS Assistant Professor, UCSF IPF Medications: Practical Experience Disclosures Received speakers bureau honorarium from Roche/Genentech (makers of pirfenidone). Brett Ley, MD, MAS Assistant Professor, UCSF 67 y/o man 1 year cough

More information

Liebow and Carrington's original classification of IIP

Liebow and Carrington's original classification of IIP Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans

More information

Interstitial Lung Disease

Interstitial Lung Disease Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation

More information

Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic

Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic Brett Ley, MD University of California San Francisco CTS 1/26/18 Disclosures Speaker s bureau honorarium from Genentech (makers of pirfenidone)

More information

Regulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1).

Regulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.05 Subject: Ofev Page: 1 of 5 Last Review Date: March 17, 2017 Ofev Description Ofev (nintedanib)

More information

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD)

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD) ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the

More information

Challenges in the classification of fibrotic ILD

Challenges in the classification of fibrotic ILD Review SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; Suppl. 1: 4-9 Mattioli 1885 Challenges in the classification of fibrotic ILD Elisabeth Bendstrup 1, Toby M. Maher 2, Effrosyni D. Manali

More information

COI: no conflicts of interest to declare

COI: no conflicts of interest to declare Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion

More information

Interstitial Lung Disease

Interstitial Lung Disease Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation

More information

Interstitial Lung Disease ILD: Definition

Interstitial Lung Disease ILD: Definition Interstitial Lung Disease 2007 Paul F. Simonelli,, MD, PhD, FCCP Clinical Director Center for Interstitial Lung Disease Columbia University Medical Center 1. ILD is not one disorder ILD: Definition 2.

More information

Perspectives ILD Diagnosis and Treatment in 5-10 years

Perspectives ILD Diagnosis and Treatment in 5-10 years Perspectives ILD Diagnosis and Treatment in 5-10 years Brett Ley, MD Department of Medicine The (Near) Future of ILD Diagnosis and Treatment 1. Combination therapy for Idiopathic Pulmonary Fibrosis 2.

More information

In idiopathic pulmonary fibrosis (IPF) and

In idiopathic pulmonary fibrosis (IPF) and Eur Respir J 2010; 35: 830 835 DOI: 10.1183/09031936.00155108 CopyrightßERS Journals Ltd 2010 Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

More information

Diffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious

Diffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious Focused Issue of This Month Diagnostic Approaches to Diffuse Interstitial Lung Diseases Dong Soon Kim, MD Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine E -

More information

Déjà vu all over again

Déjà vu all over again Disclosures Déjà vu all over again None Jonathan Singer MD MS University of California, San Francisco HPI 49 y/o woman presents for lung transplant evaluation for Hypersensitivity Pneumonitis Exposures:

More information

Strategies for Updated Treatment Options for IPF

Strategies for Updated Treatment Options for IPF Strategies for Updated Treatment Options for IPF Paul W. Noble, MD Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine Professor and Chair Department of Medicine Director, Women's Guild

More information

PIRFENIDONE. London New Drugs Group APC/DTC Briefing Document. December 2011

PIRFENIDONE. London New Drugs Group APC/DTC Briefing Document. December 2011 Page 1 London New Drugs Group APC/DTC Briefing Document PIRFENIDONE Contents Summary 1 Background 4 Current Therapy 4 Pirfenidone 4 CAPACITY studies 5 Supportive studies 7 Safety 9 Place in therapy 9 Reference

More information

Experience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina

Experience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina ORIGINAL 131 RAMR 2017;2:131-135 ISSN 1852-236X Correspondence Gabriela Tabaj gabrielatabaj@gmail.com Received: 11.15.2016 Accepted: 02.03.2017 Experience with the Compassionate Use Program of nintedanib

More information

Challenges in Pulmonary and Critical Care: 2018

Challenges in Pulmonary and Critical Care: 2018 Challenges in Pulmonary and Critical Care: 2018 Interstitial Lung Disease: Evolving Our Understanding of a Deadly Disease 1 Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical Care Medicine

More information

DM SEMINAR AUGUST 13, 2004

DM SEMINAR AUGUST 13, 2004 DM SEMINAR AUGUST 13, 2004 IDIOPATHIC INTERSTITIAL PNEUMONIAS - UPDATE Navneet Singh Department of Pulmonary Medicine HEADINGS INTRODUCTION CLASSIFICATION APPROACH TO PATIENT WITH IIP CLINICAL-RADIOLOGICAL-

More information

Pirfenidone: an update on clinical trial data and insights from everyday practice

Pirfenidone: an update on clinical trial data and insights from everyday practice REVIEW IDIOPATHIC PULMONARY FIBROSIS Pirfenidone: an update on clinical trial data and insights from everyday practice Michael Kreuter 1,2 Affiliations: 1 Dept of Pneumology and Respiratory Critical Care

More information

Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy

Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy Idiopathic Pulmonary Fibrosis Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy JMAJ 46(11): 469 474, 2003 Yukihiko SUGIYAMA Professor, Division of Pulmonary Medicine, Department of

More information

PNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera

PNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera PNEUMOLOGIA 2018 Milano, 14 16 giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE Il futuro dell : dove stiamo andando Carlo Albera Università di Torino, Scuola di Medicina Dipartimento di Scienze Cliniche e

More information

Management of Idiopathic Pulmonary Fibrosis

Management of Idiopathic Pulmonary Fibrosis Management of Idiopathic Pulmonary Fibrosis Robert Hallowell, M.D. December 22, 2015 Disclosures No financial disclosures What causes IPF? +? VEGF-R Airspace lining TNFa Fibrocytes PDGF Fibroblasts IL-1

More information

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis JULIE A. BJORAKER, JAY H. RYU, MARK K. EDWIN, JEFFREY L. MYERS, HENRY D. TAZELAAR, DARRELL R. SCHROEDER, and KENNETH

More information

Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis

Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Editorial Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Tomoo Kishaba Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Okinawa, Japan

More information

Current diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM

Current diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University

More information

Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust

Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust Interstitial Lung Disease (ILD) Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust The views expressed in this presentation are those of the speaker and are not necessarily those

More information

ESBRIET (pirfenidone) oral capsule and oral tablet OFEV (nintedanib) oral capsule

ESBRIET (pirfenidone) oral capsule and oral tablet OFEV (nintedanib) oral capsule OFEV (nintedanib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Diagnostic challenges in IPF

Diagnostic challenges in IPF Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from

More information

Challenges in the Diagnosis of Interstitial Lung Disease

Challenges in the Diagnosis of Interstitial Lung Disease Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification

More information

Challenges in the Diagnosis of Interstitial Lung Disease

Challenges in the Diagnosis of Interstitial Lung Disease Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification

More information

Epidemiology and classification of smoking related interstitial lung diseases

Epidemiology and classification of smoking related interstitial lung diseases Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207

More information